These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 8205598)

  • 21. Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes.
    Abdel-Maksoud M; Sazonov V; Gutkin SW; Hokanson JE
    J Cardiovasc Pharmacol; 2008 Apr; 51(4):331-51. PubMed ID: 18427276
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evidence of combined therapy of dyslipoproteinemia by HMG-CoA reductase inhibitors and "essential" phospholipids.
    Gurevich VS; Bondarenko BB; Mikhailova IA; Kasennova NI; Popov YuG ; Astashkina ; Le Van Thach TD
    Clin Ter; 1993 Apr; 142(4):329-34. PubMed ID: 8330475
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Drug therapy of hypercholesterolemia. Treatment of hypercholesterolemia in adults--a Norwegian therapeutic program 1988].
    Ose L; Blomhoff JP; Torsvik H
    Tidsskr Nor Laegeforen; 1989 Mar; 109(7-8):850-2. PubMed ID: 2705170
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HMGCoA reductase inhibitors lovastatin and simvastatin in the treatment of hypercholesterolemia after renal transplantation.
    Castelao AM; Griñó JM; Andrés E; Gilvernet S; Serón D; Castiñeiras MJ; Roca M; Galcerán JM; González MT; Alsina J
    Transplant Proc; 1993 Feb; 25(1 Pt 2):1043-6. PubMed ID: 8442035
    [No Abstract]   [Full Text] [Related]  

  • 25. Comparative study of the efficacy and tolerability of policosanol and lovastatin in patients with hypercholesterolemia and noninsulin dependent diabetes mellitus.
    Crespo N; Illnait J; Más R; Fernández L; Fernández J; Castaño G
    Int J Clin Pharmacol Res; 1999; 19(4):117-27. PubMed ID: 10939029
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tolerability and effects on lipids of ezetimibe coadministered with pravastatin or simvastatin for twelve months: results from two open-label extension studies in hypercholesterolemic patients.
    Strony J; Hoffman R; Hanson M; Veltri E
    Clin Ther; 2008 Dec; 30(12):2280-97. PubMed ID: 19167588
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of severe, resistant familial combined hyperlipidemia with a bezafibrate-lovastatin combination.
    Yeshurun D; Abukarshin R; Elias N; Lanir A; Naschitz JE
    Clin Ther; 1993; 15(2):355-63. PubMed ID: 8519043
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia.
    Lee SH; Chung N; Kwan J; Kim DI; Kim WH; Kim CJ; Kim HS; Park SH; Seo HS; Shin DG; Shin YW; Shim WJ; Ahn TH; Ho Yun K; Yoon MH; Cha KS; Choi SW; Han SW; Hyon MS
    Clin Ther; 2007 Nov; 29(11):2365-73. PubMed ID: 18158077
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relative effectiveness of niacin and lovastatin for treatment of dyslipidemias in a health maintenance organization.
    O'Connor PJ; Rush WA; Trence DL
    J Fam Pract; 1997 May; 44(5):462-7. PubMed ID: 9152263
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of increasing high-density lipoprotein cholesterol and decreasing low-density lipoprotein cholesterol on the incidence of first acute coronary events (from the Air Force/Texas Coronary Atherosclerosis Prevention Study).
    Cui Y; Watson DJ; Girman CJ; Shapiro DR; Gotto AM; Hiserote P; Clearfield MB
    Am J Cardiol; 2009 Sep; 104(6):829-34. PubMed ID: 19733719
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [New possibilities of correction of hypercholesterolemia in patients with diabetes mellitus].
    Pan'kiv VI
    Lik Sprava; 2014; (5-6):56-67. PubMed ID: 25906648
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lovastatin: an HMG-CoA reductase inhibitor for lowering cholesterol.
    Frishman WH; Rapier RC
    Med Clin North Am; 1989 Mar; 73(2):437-48. PubMed ID: 2645482
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lovastatin: cholesterol-lowering agent.
    DiPalma JR
    Am Fam Physician; 1987 Dec; 36(6):189-92. PubMed ID: 3687679
    [No Abstract]   [Full Text] [Related]  

  • 34. Effect of lovastatin and bezafibrate on cyclosporine-induced hyperlipidemia in rabbits.
    Hidalgo L; López-Miranda J; Espino A; Alcala J; Blanco J; Prada JL; Rodríguez M; Jiménez-Perepérez JA; Jansen S; Pérez-Jiménez F
    Transplant Proc; 1995 Apr; 27(2):1857-61. PubMed ID: 7725532
    [No Abstract]   [Full Text] [Related]  

  • 35. [Changes in the rate of cholesterol synthesis in lymphocytes, and blood lipid and lipoprotein levels in patients with ischemic heart disease and hypercholesterolemia during treatment with lovastatin and obsidan].
    Poliakova ED; Ivanova TN; Nikulina SE; Metel'skaia VA; Olfer'ev AM; Shcherbakova IA; Akhmedzhanov NM; Perova NV
    Biull Eksp Biol Med; 1994 Mar; 117(3):248-51. PubMed ID: 8204840
    [No Abstract]   [Full Text] [Related]  

  • 36. Renal transplantation and dyslipidemia: characterization of a population and treatment with diet and low dose lovastatin.
    Downey P; Maiz A; Vaccarezza A; Pinto C; Retamal F; Martínez L
    Transplant Proc; 1995 Apr; 27(2):1803-5. PubMed ID: 7725511
    [No Abstract]   [Full Text] [Related]  

  • 37. The clinical efficacy and safety of lovastatin and MK-733--an overview.
    Walker JF; Tobert JA
    Eur Heart J; 1987 Aug; 8 Suppl E():93-6. PubMed ID: 3315683
    [No Abstract]   [Full Text] [Related]  

  • 38. [Effects of lovastatin therapy on the level of low density lipoproteins and atherogenic potential of serum in patients with ischemic heart disease and hypercholesterolemia].
    Kacharava AG; Tertov VV; Zhukova IM; Orekhov AN
    Kardiologiia; 1992 Jun; 32(6):21-3. PubMed ID: 1405286
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Effect of long-term treatment with fenofibrate on serum lipids and lipoproteins in patients with hypercholesterolemia and hypertriglyceridemia].
    Sznajderman M
    Pol Tyg Lek; 1986 Dec 22-29; 41(51-52):1633-7. PubMed ID: 3588382
    [No Abstract]   [Full Text] [Related]  

  • 40. HMG-CoA reductase inhibitors. A new approach to the management of hypercholesterolemia.
    Cressman MD; Hoogwerf BJ; Moodie DS; Olin JW; Weinstein CE
    Cleve Clin J Med; 1988; 55(1):93-100. PubMed ID: 3277742
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.